Ghobadi on the Correlation Between CD8/CD4 Ratio and Responses to Blinatumomab in Patients With DLBCL

News
Video

Ghobadi explained an interesting correlation found in the results of his study presented at the 2020 ASH Annual Meeting & Exposition.

In an interview with CancerNetwork®, Armin Ghobadi, MD, of the Washington University School of Medicine in St. Louis, Missouri, explained the association between a higher CD8/CD4 ratio for patients with diffuse B-cell lymphoma who were still in remission at the median follow-up and durable responses after blinatumomab (Blincyto) treatment in a study (NCT03072771) presented at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.

Transcription:

When we looked at those who are still in remission up to 15 months later versus those who relapsed, interestingly, we found out that the ratio of CD8 to CD4 before they started blinatumomab and after BEAM [carmustine, etopside, cytarabine, and melphan] and autologous transplant was significantly higher in those patients still in remission 15 months later. And that has been reported in other studies. Basically, blinatumomab [is] bringing in T-cells, effector cells, to go after the lymphoma cells. And in this case, having a higher ratio of CD8 to CD4 was associated with durable response even after 1 cycle of blinatumomab.

Recent Videos
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content